glp-1 novo nordisk cuts prices for cash buyers Novo Nordisk testing its blockbuster

FDA-approved GLP-1 agonists include exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), and others

However, tirzepatide demonstrates a dose-dependent effect on glycaemia: at 5 mg once weekly, 27% of people with type 2 diabetes achieved an HbA 1c below 5.7%, compared with 46% at 15 mg once weekly

Other weight loss medications to consider Numerous medications are on the market for weight loss (Editors note: See FDA-Approved Medications to Treat Obesity table below)

LlewellynSmith et al., 2011) and thus might be a target for central GLP1 under physiological conditions as well as for truly supraphysiological amounts of circulating GLP1 and GLP1 receptor agonists

The cost for each drug can easily exceed $1000 per month

Regulatory authorization for new drug for first indication, defined as Novel Drug Approval by FDA, and Marketing Authorization for New Active Substance by EMA.